Working closely with the Founder and Chairman, Allan’s role is to prioritize key activities, manage operations, plan fundraising, and ensure that the company’s scientific vision is effectively translated into operational and product successes. He guides the strategic direction and execution of the company’s drug research and development programs. His role includes serving as a management team member in Bessor’s subsidiary, REMeD Therapeutics. He previously served as Bessor’s VP Licensing and General Counsel.

Allan has over 30 years of experience as a biotech management team member, corporate lawyer, and accountant. Previously, he served as VP Transactions and Legal at Novavax, headed the legal and transactions function at Auven Therapeutics and Celtic Pharma, hybrid venture capital and virtual drug development firms.

Prior to joining Celtic, he was interim General Counsel of computational chemistry company Schrödinger, worked in the general counsel's offices at Goldman Sachs and American Express, served as general counsel of a publicly-traded technology incubator, worked as a corporate attorney at McDermott, Will & Emery, and served on the Audit and Advisory team at Arthur Andersen. Allan earned a J.D. from the University of Virginia School of Law and a B.S. in Accounting from Penn State.